[1] COMPERAT E,AMIN M B,CATHOMAS R,et al. Current best practice for bladder cancer:a narrative review of diagnostics and treatments[J]. Lancet,2022,400(10364):1712-1721.
[2] STONE L. Subtypes in small cell bladder cancer[J]. Nat Rev Urol,2023,20(9):521.
[3] LENISAT,LEC P M,CHAMINE K,et al. Bladder cancer:a review[J]. JAMA,2020,324(19):1980-1991.
[4] 李雪,马艳春,赵婧含,等. 肉桂的化学成分及药理作用研究进展[J]. 药学研究,2024,43(10):1015-1020.
[5] NILE A,SHIN J,SHIN J,et al. Cinnamaldehyde-rich cinnamon extract induces cell death in colon cancer cell lines HCT 116 and HT-29[J]. Int J MolSci,2023,24(9):8191.
[6] 洪恺祺,陈丽,朱镇华,等. 肉桂醛通过PINK1/Parkin信号通路介导的线粒体自噬促进糖尿病大鼠创面愈合机制[J]. 中国实验方剂学杂志,2023,29(16):134-143.
[7] 牟悦,王雪振,王世军,等. 肉桂醛调节肿瘤的作用及机制研究进展[J]. 中华中医药杂志,2023,38(1):294-297.
[8] 周凌,晏洪波. 肉桂醛对UVA照射后体外成纤维细胞表达MMP-1,MMP-3和MAPK信号的影响[J]. 中国皮肤性病学杂志,2015,29(2):114-117.
[9] HAORAN E,ZHANG L,YANG Z,et al. SNAI1 promotes epithelial-mesenchymal transition and maintains cancer stem cell-like properties in thymic epithelial tumors through the PIK3R2/p-EphA2 axis[J]. J Exp Clin Cancer Res,2024,43(1):324.
[10] 陈秀婷,杨莹莹,王佳琪,等. 肉桂醛缓解高糖诱导的SH-SY5Y细胞铁死亡的作用研究[J]. 中药药理与临床,2024,12(1):12-17.
[11] 褚鹿鹿,郭智慧,侯婧悦,等. 肉桂醛防治糖尿病的药理作用研究进展[J]. 现代药物与临床,2023,38(2):483-487.
[12] 赵宁宁,胡亦杨,谢瑛莹,等. 天然化合物通过抑制VEGF抗血管生成抗肿瘤的研究进展[J]. 中华中医药学刊,2024,5:18-21
[13] WILSON K,SHIUAN E,BRANTLEY D M. Oncogenic functions and therapeutic targeting of EphA2 in cancer[J]. Oncogene,2021, 40(14):2483-2495.
[14] TOMIYAMA E,FUJITA K,MATSUZAKI K,et al. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer[J]. Br J Cancer,2022,127(7):1312-1323.
[15] BURASCHI S,NEILL T,XU S Q,et al. Progranulin/EphA2 axis:a novel oncogenic mechanism in bladder cancer[J]. Matrix Biol,2020, 93:10-24.
[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer(≤pT2N0M0)[J].Journal of Tianjin Medical University,2017,23(03):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(03):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(03):51.
[5]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(03):373.
[6]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(03):39.
[7]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(03):445.
[8]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[9]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(03):621.
[10]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.